Therapeutic Response

FLT3-ITD status confers therapeutic sensitivity to Cytarabine in combination with Quizartinib in patients with Acute Myeloid Leukemia.

Statements

Source and description
Quizartinib and Intermediate Dose Cytarabine Consolidation Therapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved quizartinib in combination with cytarabine consolidation chemotherapy as a treatment option for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who are FLT3-ITD mutation positive.